Name: UMIN ID:
Unique ID issued by UMIN | UMIN000012175 |
---|---|
Receipt number | R000014233 |
Scientific Title | Phase II trial of Cisplatin and Irinotecan treatment as palliative-intended chemotherapy for previously untreated advanced thymic carcinoma |
Date of disclosure of the study information | 2013/11/30 |
Last modified on | 2019/03/22 12:31:49 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2013/10/30 20:56:36 | ||
2 | Update | 2013/11/29 14:05:53 | Anticipated trial start date |
|
3 | Update | 2013/11/29 14:07:00 | Recruitment status |
|
4 | Update | 2016/04/01 15:11:34 | Name of primary person or sponsor Organization |
|
5 | Update | 2016/04/07 23:33:36 | Name of primary person or sponsor Organization |
|
6 | Update | 2016/04/07 23:39:14 | Name of primary person or sponsor Organization |
|
7 | Update | 2018/05/20 10:04:31 | Recruitment status |
|
8 | Update | 2019/03/22 12:29:07 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Organization Zip code Address Organization Organization Address Address Tel |
|
9 | Update | 2019/03/22 12:29:50 | Date of IRB Last follow-up date Date of closure to data entry |
|
10 | Update | 2019/03/22 12:31:49 | URL releasing protocol URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Results Delay Reason Results Delay Reason Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |